Cardiovascular disorders are the most common type of diseases responsible for more than 15 million deaths worldwide annually. While standard clinical interventions have resulted in improved patient outcomes, the motivation for innovation contrary to current limitations in the field of engineered biomaterials continue progressively.We plan to present the current status of technology employed briefly, cite ongoing research and discuss the needs and expectations of this type of surgical disciplines in the near future.Concepts will cover our ongoing projects on cellular therapy (mitochondria transplantation, stem cell applications), artificial intelligence (cardiac radiology/angiography), stents, anti-inflammatory strategies in cardiopulmonary bypass (mini-circuitry, filtration), patient blood management (pharmaceuticals, salvaged blood, cell-saver, artificial blood), nanotechnology (myocardial protection), biosensors (biochemistry, hematology), extracorporeal life support systems, organ preservation and hot topics/interventions regarding COVID-19 infection.

About the Speaker:

Dr. Gunaydin received his cardiac surgical training in Turkey, England, and the Netherlands and worked as a clinical fellow in Heinrich Heine University in Dusseldorf-Germany and the Heart Institute of Japan. He studied histology and embryology for three years and completed his PhD in Tissue Engineering and Biomaterial Science at Tokyo University. Dr. Gunaydin currently serves as clinical professor in Ankara City Hospital, University of Health Sciences, Ankara. He is visiting lecturer in Hacettepe University-Ankara-Turkey; Biomedical Research Foundation, Academy of Athens - Greece; Bioengineering Unit in Strathclyde University, Glasgow-UK and Lankenau Institute of Medical Research in Philadelphia-USA. He is the chairman of the sicentific board in Heart Tema Education Association and VFPM (Verein zur Förderung der Perioperativen Medizin). Dr. Gunaydin's main research interests are clinical evaluation and biomaterial confirmation of novel cardiopulmonary bypass-related technologies based on the prevention of inflammatory response. He received Young Cardiac Surgeon Award, European Society of Cardiovascular Surgery in 2008; Cardiothoracic Surgery Foundation, 10th Utley Award in 2009 and was nominated for Gibbon Award, American Society of Extracorporeal Technology in 2011 and Times Higher Education- Innovation Award in 2013.